0000899243-18-006817.txt : 20180308 0000899243-18-006817.hdr.sgml : 20180308 20180308163854 ACCESSION NUMBER: 0000899243-18-006817 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180306 FILED AS OF DATE: 20180308 DATE AS OF CHANGE: 20180308 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Tulipano Stephen J CENTRAL INDEX KEY: 0001360548 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36332 FILM NUMBER: 18676996 MAIL ADDRESS: STREET 1: C/O JAVELIN PHARMACEUTICALS, INC. STREET 2: 125 CAMBRIDGE PARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aldeyra Therapeutics, Inc. CENTRAL INDEX KEY: 0001341235 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 131 HARTWELL AVENUE STREET 2: SUITE 320 CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-761-4904 MAIL ADDRESS: STREET 1: 131 HARTWELL AVENUE STREET 2: SUITE 320 CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: Aldexa Therapeutics, Inc. DATE OF NAME CHANGE: 20130102 FORMER COMPANY: FORMER CONFORMED NAME: Neuron Systems Inc DATE OF NAME CHANGE: 20051012 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-03-06 0 0001341235 Aldeyra Therapeutics, Inc. ALDX 0001360548 Tulipano Stephen J C/O ALDEYRA THERAPEUTICS, INC. 131 HARTWELL AVENUE LEXINGTON MA 02421 0 1 0 0 Chief Financial Officer Common Stock 2017-06-30 5 A 0 E 2077 3.9525 A 5410 D Common Stock 2017-12-29 5 A 0 E 3153 3.995 A 8563 D Employee Stock Option (Right to Buy) 8.60 2018-03-06 4 A 0 125670 0.00 A 2028-03-05 Common Stock 125670 125670 D Represents the voluntary reporting of 2,077 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan (ESPP) in June 2017. In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 30, 2017. Represents the voluntary reporting of 3,153 shares of common stock acquired under the Issuer's ESPP in December 2017. In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on July 3, 2017. The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2018. /s/ Stephen Tulipano 2018-03-08